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Abstract: Polymer-drug conjugates have significantly influenced polymer therapeutics over the last 
decade via controlled pharmacokinetics. Dapsone (4,4'-diamino diphenylsulphone) is not only widely 
used in the treatment of leprosy but forms an essential component in the treatment of autoimmune 
inflammatory diseases and malaria. However, its low bioavailability and non-specific distribution in 
the body leads to absorption throughout organs including skin, liver, and kidneys that can cause 
serious side effects. Thus, in this study we report the synthesis of polymer-drug conjugates of dapsone 
covalently bonded to macromolecular chains towards the development of new bioactive polymeric 
formulations with anti-inflammatory properties.  Dapsone was functionalised with an acrylic moiety in 
which the acrylamide residue was directly bonded to one of the aromatic rings of dapsone. This 
functionalization yielded an unsymmetrical dapsone methacrylamide (DapMA) structure, which on 
free radical polymerisation and co-polymerisation with HEMA yielded polymers of hydrocarbon 
macromolecules with pendant dapsone units. Thermal and size-exclusion chromatographic analysis 
revealed an increase in thermal stabilisation of the homopolymer (p(DapMA)) in comparison to the 
copolymer (p(Dap-co-HEMA)) with relatively high average molecular weight. The polymer conjugates 
exhibited high stability with low dapsone release from the polymeric backbone due to hydrolysis. 
However, a significant anti-inflammatory activity in a nitric oxide inhibition assay confirmed that this 
property was the consequence of only the macromolecular composition and not related to the release 
of low molecular weight compounds. Thus, the conjugation of dapsone to macromolecular systems 
provides a synthetic route to incorporate this drug into polymeric systems, facilitating their 
development into new anti-inflammatory therapies 
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this work lies in its potential to expand the clinical applications of dapsone toward the 
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Abstract 
Polymer-drug conjugates have significantly influenced polymer therapeutics over the 
last decade via controlled pharmacokinetics. Dapsone (4,4’-diamino 
diphenylsulphone) is not only widely used in the treatment of leprosy but forms an 
essential component in the treatment of autoimmune inflammatory diseases and 
malaria. However, its low bioavailability and non-specific distribution in the body 
leads to absorption throughout organs including skin, liver, and kidneys that can 
cause serious side effects. Thus, in this study we report the synthesis of polymer-
drug conjugates of dapsone covalently bonded to macromolecular chains towards 
the development of new bioactive polymeric formulations with anti-inflammatory 
properties.  Dapsone was functionalised with an acrylic moiety in which the 
*Text only
Click here to view linked References
2 
 
acrylamide residue was directly bonded to one of the aromatic rings of dapsone. This 
functionalization yielded an unsymmetrical dapsone methacrylamide (DapMA) 
structure, which on free radical polymerisation and co-polymerisation with HEMA 
yielded polymers of hydrocarbon macromolecules with pendant dapsone units. 
Thermal and size-exclusion chromatographic analysis revealed an increase in 
thermal stabilisation of the homopolymer (p(DapMA)) in comparison to the 
copolymer (p(Dap-co-HEMA)) with relatively high average molecular weight. The 
polymer conjugates exhibited high stability with low dapsone release from the 
polymeric backbone due to hydrolysis. However, a significant anti-inflammatory 
activity in a nitric oxide inhibition assay confirmed that this property was the 
consequence of only the macromolecular composition and not related to the release 
of low molecular weight compounds. Thus, the conjugation of dapsone to 
macromolecular systems provides a synthetic route to incorporate this drug into 
polymeric systems, facilitating their development into new anti-inflammatory 
therapies 
Keywords 
Dapsone, HEMA, polymer-drug conjugate, anti-imflammatory polymers, nitric oxide 
inhibition assay 
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1. Introduction 
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During the last century, sulfone derivatives have been extensively used in 
medicine because of their versatile bioactive, biocidic and anti-inflammatory 
properties. Dapsone is structurally one of the simplest sulfones but also recognised 
as an active therapeutic agent from this family of compounds. As an antibiotic, 
dapsone acts against bacteria and protozoa inhibiting the synthesis of dihydrofolic 
acid through competition with para-aminobenzoate for the active site of 
dihydropteroate synthease [1]. In addition, dapsone has been successfully used as 
an essential component for the treatment and prophylaxis of leprosy, 
actinomycetoma, Pneumocystis pneumonia, and malaria. The anti-inflammatory 
action of the drug is not related with its antibacterial action and is still not fully 
understood. Dapsone has been reported to interfere with the activation or function of 
a large number of polymorphonuclear leukocytes, predominantly neutrophils and 
eosinophils, into the affected tissue and shows a noticeable activity in reducing or 
suppressing the symptoms of many autoimmune [2] and skin [3] related diseases 
such as acne fulminas, actionomycetoma, brown recluse spider bites, celiac disease, 
cicratical pemphigoid, dermatitis herpetiformis, bullous pemphigoid, Behcet’s 
disease, and lupus erythematous.  
One of the main disadvantages of oral administration of dapsone stems from 
its low solubility and non-specific distribution in the body, once absorbed, it is 
distributed throughout the organs in the body including skin, liver, and kidneys [4]. 
Dapsone has also been reported to cross the blood-brain barrier and the placenta 
and is found in breast milk [5, 6]. Hence, dapsone therapies are still associated with 
drawbacks of hemolysis, methemoglobinemia and patient non-compliance [7]. To 
render the treatment more effective and reduce these side effects, a better control 
over pharmacokinetics and site specific delivery are needed. Thus far, the design of 
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polymer formulations for controlled delivery of dapsone has been limited to 
encapsulation within polymeric systems, for which mainly polysaccharides have 
been used [8, 9]. Although these methodologies have improved the 
pharmacokinetics, the therapeutic effects of these polymer formulations were found 
to be modest and a reduction of the complications associated with dapsone 
therapies were not sufficiently achieved.  
Recent developments in the field of polymer-conjugates have provided very 
promising examples of FDA approved and marketed pharmaceutical products [10]. 
Anti-inflammatory therapies involving the incorporation of low molecular weight drugs 
into macromolecular systems such as ibuprofen and aspirin polymer-drug conjugates 
have shown promising advances that enhance the bioavailability and compatibility 
within the body [11, 12]. Nonetheless, biomedical approaches based on dapsone 
polymer-drug conjugates have not yet been fully exploited. Chemically incorporating 
4, 4’-diamino diphenylsulphone (dapsone) into a polymer system has only been 
reported in elastomeric formulations for engineering applications based on its 
capacity to act as a curing agent in epoxy resins. This results in a high performance 
elastomeric material with enhanced thermal and mechanical properties, composite 
materials, and structural adhesives that are unrelated to the current work [13].  
In view of the limitations of current dapsone treatment, a polymer system that 
intrinsically contains the active dapsone molecule anchored to the macromolecular 
polymer structure will be extremely beneficial and efficacious for therapeutic action. 
This would lead to enhanced control of pharmacokinetics whilst providing a novel 
approach for safe use of this promising drug. The covalent linking of dapsone into 
macromolecular chains is advantageous as it will reduce the migration of dapsone 
into the surrounding tissues and improve hydrolytic and biological stability. 
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This study reports for the first time the synthesis and characterisation of a 
polymerisable derivative of dapsone, dapsone methacrylamide (DapMA) (Figure 1) 
and the polymers thereof. These systems have the potential for the development of 
bioactive polymeric formulations with anti-inflammatory properties by virtue of the 
dapsone residues anchored to the macromolecular chains, which have not yet been 
reported. 
2. Materials and Methods 
2.1. Chemicals 
Dapsone (97 %) was purchased from Aldrich and recrystallised from methanol. 
Methacryloyl chloride (97 %, Aldrich) and triethylamine (98 %, Scharlau) were 
purified by distillation under reduced pressure. 2-Hydroxyethyl methacrylate (HEMA) 
(97 %, Sigma–Aldrich) was purified according to the literature by water-hexane 
selective extraction and washing [14]. 2,2-Azobisisobutyronitrile (AIBN) (98 %, 
Merck) was recrystallised using methanol. Ethylene glycol dimethacrylate (EGDMA) 
(98%, Aldrich) was used as received. Solvents used were high performance liquid 
chromatography (HPLC) grade and all other reagents were analytical grade 
purchased form Sigma-Aldrich.  
Phosphate-buffered solution (PBS) of pH 7.4 (Sigma) was used as received. 
Thermanox (TMX) control disks were supplied by Labclinics S. L., and aqueous 
solutions of Triton X-100 were supplied by Aldrich. Tissue culture media, additives, 
trypsin, and 3-(4,5 dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) were 
purchased from Sigma. 
2.2. Synthesis of Dapsone Methacrylamide monomer  
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Dapsone (4g, 16 mmol) was dissolved in 150 mL of ethyl acetate containing 
triethylamine (2.8 mL, 20 mmol). A stoichiometric amount of methacryloyl chloride 
(1.2 mL, 16 mmol) dissolved in 10 mL of ethyl acetate was added dropwise with 
constant stirring at room temperature under nitrogen atmosphere, followed by stirring 
the reaction mixture for a further 24 h at room temperature. The reaction medium 
was filtered to remove the triethylamine hydrochloride and any unreacted reagents 
were removed by successive extraction with 0.5M HCl and saturated solutions of 
HNaCO3 and NaCl. After drying over anhydrous Na2SO4, the solvent was removed 
by distillation under reduced pressure and the crude product was purified by a triple 
recrystallisation in methanol, ethyl acetate, followed by diethyl ether and dried under 
vacuum until constant weight. 
2.3. Synthesis of poly(dapsone methacrylate) homopolymer and  poly(hydroxyethyl 
methacrylate-co-dapsone methacrylate) co-polymer.  
Homopolymer p(DapMA) and co-polymer p(DapMA-co-HEMA) (50% feed 
molar ratio) were synthesized by free radical polymerisation and named P100 and 
P50, respectively. The appropriate co-monomer mixtures were dissolved in DMF ([M] 
= 0.25 mol · L-1) containing AIBN (1.5 · 10-2 mol · L-1), and the reaction mixtures were 
deoxygenated with N2 for 15 min and the reaction containers were then transferred 
to an oven at 50 °C for 24 h. After this period, the reaction mixture was precipitated 
in ethanol and centrifuged for 5 min at 6·103 rpm. The product obtained was re-
suspended in fresh ethanol and centrifuged again. The final product was filtered, 
washed with fresh ethanol and dried under vacuum to constant weight. 
Cross-linked polymers and co-polymers were additionally prepared by 
dissolving the corresponding monomer mixture in 0.4 mL of DMF ([M] = 1 mol · L-1) 
containing AIBN (1.5·10-2 mol · L-1) and EGDMA (1 mol%) as crosslinking agent.  
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The reaction mixtures were deoxygenated with N2 for 15 min, sealed in 
polypropylene cylindrical moulds (12 mm in diameter) and transferred to an oven at 
50 °C for 24 h. After this period the gels were demoulded rinsed with DMF in order to 
remove all unreacted products and extensively washed with methanol in an orbital 
shaker by replacing the medium every 30 minutes for 4 hours. After this cycle the 
samples were dried under vacuum at 30 °C to constant weight. 
2.4. Characterisation techniques 
1H and 13C NMR spectra were recorded on an INOVA-300 spectrophotometer, 
operating at 300 and 75.5 MHz, respectively. The spectra were recorded by 
dissolving the corresponding sample (10% w/v) in deuterated dimethylsufoxide 
(DMSO-d6) and using tetramethylsilane (TMS) as internal standard at 25 °C. An 
indirect detection experiment, heteronuclear multiple quantum coherence (HMQC), 
was performed to observe correlation between carbon-13 nuclei while detecting 
high-sensitivity protons. A pulse delay of 3 s between 90° pulses (13.5 s), 32 scans, 
and 1024 data points for t1 increment, of 256 increments, sweep width of 2500 Hz in 
the F2 dimension and 13,000 Hz in the F1 dimension were used in the experiment 
with gap decoupling of carbon-13.  
ATR-FTIR fingerprint region spectra were recorded on a Perkin–Elmer 
Spectrum One spectrophotometer with an ATR attachment from 550 to 2,000 cm-1 
with a resolution of 4 cm-1 and transmittance scales were normalized for all recorded 
spectra. 
Mass spectra were obtained with an electrospray ionization mass spectrometer 
(Agilent Series 1100) using 1mg/ml solutions in H2O/methanol/acetonitrile 
(49.5/49.5/1 vol%) as mobile phase. 
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Number (Mn) and weight (Mw) average molecular-weight distribution and 
polydispersity index (PI=Mw/Mn) were determined by size exclusion chromatography 
(SEC) (Perkin–Elmer) using polymer solutions in DMF (3 mg · mL-1) with LiBr (0.1% 
w/v) at a flow rate of 0.3 mL · min-1, using two ResiPore columns (250mm - 4.6mm, 
Varian) thermostated at 70 °C and a differential refractometer as detector. Mn and 
Mw were determined based on the calibration curve obtained from monodisperse 
poly(methylmethacrylate) (PMMA) (Perkin) standard samples.  
Glass transition temperatures (Tg) were measured by differential scanning 
calorimetry (DSC, Perkin–Elmer DSC 8500). Samples (15 mg) were placed in 
aluminium pans and heated under nitrogen flow (20mL · min-1) from -20 to 190 °C at 
constant rate of 10 °C · min-1. Tg was taken as the midpoint of the heat capacity 
transition observed. Thermogravimetric diagrams were obtained using a 
thermogravimetric analyser using a TGA Q500 (TA instruments) apparatus, under a 
stream of nitrogen at a heating rate of 5 °C · min-1 from 40 - 600 °C. 
2.5. In vitro drug release, degradation, cell culture, cytotoxicity and anti-
inflammatory activity of dapsone derivatives. 
In vitro drug release and degradation studies were carried out using crosslinked 
P100 and P50 disk shaped samples of 12mm in diameter. In vitro dapsone release 
from each composition was studied by soaking three different crosslinked samples in 
2 mL of three different release media at pH 3, 7 and 10 buffered solutions and at 37 
°C under continuous agitation using an orbital shaker. At desired time points, the 
medium was refreshed under sterile conditions. The extracts were mixed with 
methanol (1:1 v/v) for dapsone release and quantification was done by UV 
spectroscopy detection at 295 nm using a Perking Elmer Lambda 16 instrument. 
Known concentration solutions of dapsone (0 – 10 g · mL-1) were used for 
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calibration purposes (R2>0.99). Degradation of each composition was studied by 
gravimetric measurements before and after soaking three different crosslinked 
samples in 1 mL of PBS buffered solutions maintained at 37 °C under continuous 
agitation using an orbital shaker. At each desired time point, three different samples 
were used and consequently dried and weighed. All the experiments were carried 
out in triplicate. 
Cell culture studies were performed using monocyte macrophages RAW 
264.7 (ECACC, Sigma, P8) cells. The culture medium was Dulbecco’s modified 
Eagle’s medium enriched with 110 mg · mL-1 of sodium pyruvate (DMEM, Sigma) 
and supplemented with 10 vol% of fetal bovine serum (FBS, Gibco), 200mM L-
glutamine, 100 units · mL-1 penicillin, and 100 mg · mL-1 streptomycin. Cultures were 
maintained at 37 °C in humidified air with 5 vol% CO2, and the culture medium was 
carefully replaced at selected time intervals under sterile conditions. 
The cytotoxicity of the compounds were assessed by MTT assay. 0.5 mg · 
mL-1 solutions of linear p(DapMA) and p(DapMA-co-HEMA) copolymer prepared in 
water and were successively diluted to a concentration range of 0.5 - 2·10-4 mg · mL-
1. Cells were seeded in a sterile 96-well culture plate at a density of 5 · 104 cells · mL-
1 in complete medium and incubated to confluence for 24 h. Following this 50 mL of 
each sample dilution were added (n = 8) and incubated for 24, 48, and 72 h. After 
each time point, the medium was removed and 100 mL MTT solution prepared in 
warm PBS (0.5 mg · mL-1) was added to each well and plates incubated at 37 °C for 
4 h. The excess medium and MTT were then removed and 100 mL of DMSO was 
added to each well in order to dissolve the formazan produced by viable cells. The 
absorbance was measured using a test wavelength of 570 nm (Biotek ELX808 IU 
detector). 
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Samples with a cell viability over 70% were selected for the determination of 
the anti-inflammatory activity by the nitric oxide inhibitory method reported by Wang 
et al [15]. Briefly, raw cells were seeded at a density of 5 · 104 cells · mL-1 in 
complete medium in a sterile 96-well culture plate and incubated for 24 h. Adhered 
cells were then incubated with or without 1 mg · mL-1 of lipopolysaccharide (LPS) 
(Escherichia coli 0127:138, Sigma-Aldrich) for 30 min when 50 mL of the respective 
polymer solutions were added and incubated at 37 °C for other 24 h. Nitrite 
concentration was measured by the Griess reaction [16] using 150 mL of the cell 
supernatants with 150 mL of an aqueous solution (13.33 vol%) of Griess reagent [1:1 
mixture of 0.1 wt% N-(1-naphtyl) ethylenediamine in H2O and 1wt% sulphanilamide 
in 5 wt% phosphoric acid] in a 96-well plate and the absorbance was recorded after 
30 min of reaction at 540 nm. A NaNO2 curve was used as an external calibration 
(R2>0.99). An additional MTT assay was performed as described above for the 
calculation of the corresponding dose-response curves of relative cell viability of the 
treated cells with the LPS to delineate the concentrations of the sample that 
depressed MTT-formazan production by 50% (IC50 value). The results were 
normalised respect to the corresponding blanks, and statistically tested with ANOVA 
(p<0.05). 
3. Results  
3.1. Dapsone Methacrylamide monomer  
Dapsone was functionalised with an acrylic moiety, in which the 
methacrylamide residue was directly bonded to one of the aromatic rings of dapsone 
leading to unsymmetrical structure of DapMA forming a white powder with a yield 
52% after the recrystallization procedure. The reaction scheme for the acylation of 
dapsone is illustrated in Figure 2 and the DapMA monomer was characterized by 1H 
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and 13C NMR spectroscopy and both and HMQC spectra are respectively illustrated 
in Figures 3 and 4 showing the following peak assignment: 
1H-NMR spectrum DapMA (DMSO-d6): H 10.13 (1H, CO-NH-CAr-SO2), 7.83  , 
J = 7.9 Hz (2HAr, CO-NH-C-CH-CH-C-SO2), 7.76 (2HAr, NH2-C-CH-CH-C-SO2), 7.51, 
J = 8.7 Hz (2HAr, CO-NH-C-CH-CH-C-SO2), 6.62, J = 8.7 Hz (2HAr, NH2-C-CH-CH-C-
SO2), 6.11 (2H, NH2-CAr), 5.80 and 5.54 (2H, CH2=C(CH3)CO), 1.93 (3H, 
CH2=C(CH3)CO). 
13C-NMR spectrum DapMA (DMSO-d6): C 167.2 (CO-NH), 153.5 (NH2-C-CH-
CH-C-SO2), 143.0 (CO-NH-C-CH-CH-C-SO2), 139.9 (=C(CH3)-CON), 137.2 (CO-
NH-C-CH-CH-C-SO2), 129.18 (NH2-C-CH-CH-C-SO2) 128.5 (CO-NH-C-CH-CH-C-
SO2) 127.4 (NH2-C-CH-CH-C-SO2), 120.8 (C
H2), 119.9 (CO-NH-C-CH-CH-C-SO2), 
113.0 (NH2-C-CH-CH-C-SO2), 18.5 (C
H3) 
3.2. Dapone Methacrylamide homopolymer and co-polymer  
The dapsone methacrylamide was used for both homo and copolymerisation 
with HEMA.  Linear p(DapMA) (P100) and p(DapMA-co-HEMA) (P50) copolymers of 
HEMA with dapsone (Figure 2) were synthesized by free radical polymerisation 
using AIBN in dimethylformamide as solvent at 50 °C and both obtained in the form 
of white powders and soluble in organic solvents such as DMSO and DMF and N,N-
dimethylacetamide.  Solubility in water is limited but confirmed at concentrations of 
0.5 mg · mL-1 or less. P100 and P50 linear polymers were characterised by 1H and 
13C NMR spectroscopy showing the following peak assignment: 
1H-NMR spectrum p(DapMA) (DMSO-d6): H 9.3 (bs, CO-NH-CAr-SO2), 8.6 – 
6.4 (bm, CO-NH-C-CH-CH-C-SO2, NH2-C-CH-CH-C-SO2, CO-NH-C-CH-CH-C-SO2, 
NH2-C-CH-CH-C-SO2), 6.11 (bs, NH2-CAr), 2.90 - 1.7 (m, CH2
), 0.83 (bs CH3
). 
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13C-NMR spectrum p(DapMA) (DMSO-d6): C 175.9 (CO-NH), 153.5 (NH2-C-
CH-CH-C-SO2), 142.5 (CO-NH-C-CH-CH-C-SO2), 137.5 (CO-NH-C-CH-CH-C-SO2), 
129.5 (CO-C-CH-CH-C-SO2) 127.4 (CO-NH2-C-CH-CH-C-SO2) 126.1 (NH2-C-CH-
CH-C-SO2), 120.8 (CO-NH-C-CH-CH-C-SO2), 113.1 (NH2-C-CH-CH-C-SO2), 66.5 
(CH2), 46.2 (C
H3) 
1H-NMR spectrum p(DapMA-co-HEMA) (DMSO-d6): H 9.3 (bs 1H, CO-NH-CAr-
SO2), 8.3 – 6.2 (bm, CO-NH-C-CH-CH-C-SO2, NH2-C-CH-CH-C-SO2, CO-NH-C-CH-
CH-C-SO2, NH2-C-CH-CH-C-SO2), 6.10 (bs, NH2-CAr), 4.8 (bs O(CH2) 2OH),  4.35 - 
3.1 (bm O(CH2) 2OH), 2.90 - 1.5 (bm CH2
), 0.1 -  1.4  (bm CH3
). 
13C-NMR spectrum p(DapMA-co-HEMA) (DMSO-d6):  
C 179.8 - 175.5 (CO-NH, COO), 154.3 (NH2-C-CH-CH-C-SO2), 143.3 (CO-NH-
C-CH-CH-C-SO2), 138.2 (CO-NH-C-CH-CH-C-SO2), 130.2 (CO-C-CH-CH-C-SO2) 
128.1 (CO-NH2-C-CH-CH-C-SO2) 126.5 (NH2-C-CH-CH-C-SO2), 121.8 (CO-NH-C-
CH-CH-C-SO2), 113.4 (NH2-C-CH-CH-C-SO2), 66.8 (O(CH2-CH2OH), 59.3 (O(CH2-
CH2OH), 54.2 – 43.2 (C
H2), 21.3 – 13.9 (C
H3) 
3.3. Characterisation techniques 
 Figure 5 shows the 1H-NMR spectra of the homopolymer and co-polymer 
system in which the corresponding signal of each monomeric units could be 
observed. Co-polymer composition was determined from 1H NMR spectra of P50 co-
polymer sample using the integral of the hydroxyl protons signals (CH2-OH, 4.8 ppm) 
and oxyethylene protons signals at (-O(CH2)2O-, 4.3 - 3.1 ppm) and those of the 
aromatic ring protons at 6.5 - 8.4 ppm. In addition Figure 6 shows the FTIR 
fingerprint region spectra of Dapsone, DapMA monomer and linear dapsone-
conjugated polymers p(DapMA) (P100) and p(DapMA-co-HEMA) (P50) where the 
13 
 
characteristic vibrational bands to can be observed (most representative bands: 
asym,C=O 1,720 cm
-1 and 1,770 cm-1; N-H 1,619 cm
-1; C=CH2 1,639 cm
-1; ArC=C 1,589 
cm-1; SO2 1,290 cm
-1; C-N 1,280 cm
-1). 
Table 1. Composition, Glass transition Temperature (Tg), Number Average Molecular Weight (Mn) 
Polydispersity Index (P.I.) and Temperatures of maximum degradation speed (Tmax) and half weight 
loss (T50%) of p(DapMA) (P100) and p(DapMA-co-HEMA) (P50) 
Sample 
DapMA in the feed 
(mol %) 
DapMA in the 
copolymer 
(mol %) 
Tg 
(°C) 
Mn 
(Kg/mol) 
P.I. 
Tmax 
(°C) 
T50% 
(°C) 
P100 100 100 129 106 2.2 359 420 
P50 50 48 114 62 1.96 470 454 
 
Molecular weight and polydispersity determined by SEC and thermal 
characteristic of P100 and P50 polymers are summarized in Table 1. The glass 
transition temperature of the p(DapMA) homopolymer was 129 °C, which decreased 
to 114 °C with the addition of HEMA units to form the co-polymer. The thermal 
stabilities of P50 and P100 were investigated with TGA in a nitrogen stream, and the 
thermogravimetric curves are compared in Figure 7. The p(DapMA-co-HEMA) 
copolymer thermogram showed four degradation stages, and the derivative of the 
weight loss versus temperature showed four corresponding peaks centred at 250, 
301, 350, and 470 °C. In contrast, the p(DapMA) homopolymer thermogram showed 
only two main degradation stages, corresponding to peaks centred at 358 and 435 
°C.  
3.4. In vitro dapsone release, degradation, cytotoxicity and anti-inflammatory 
activity. 
Weight loss determined by gravimetric measurements showed that the 
polymers were stable when immersed in PBS solutions at 37 °C with a weight loss 
lower than 0.1 % after 21 days. The release of dapsone at three different pHs 
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(acidic, neutral, basic) is shown in Figure 8. The sustained release profiles of 
dapsone were comparable at different pH for all polymer conjugates with a slight 
increase in dapsone release for the P50 copolymers at pH 10.   
 
 
The nitric oxide (NO) inhibitory effects of the dapsone polymers on LPS 
treated cells after 24 h of incubation is shown in Figure 9 revealing significant 
inhibition on NO production compared to those of LPS-stimulated control cultures 
with no polymer drug added. In addition, the incorporation of HEMA into the co-
polymers reduced their cytotoxicity as observed in (Figure 10) for the dose-
dependent effect with IC50 values ranging between 32 and 43 g·ml-1 (Table 2). 
This revealed the absence of cytotoxic effects (CV > 99%) associated to the polymer 
extracts used for the NO inhibition studies. 
 
4. Discussion 
A typical acylation reaction was used for the synthesis of the DapMA by 
reaction with methacryloyl chloride using triethylamine as a catalyst under mild 
conditions [17]. Since dapsone contains two reactive aromatic amine functional 
groups it can lead to the formation of an undesirable side product namely bis-
acrylamide as shown in Figure 1. However, the yield of this double acylation product 
 
Table 2. In vitro parameters determined for p(DapMA) (P100) and p(DapMA-co-HEMA) (P50) 
Sample 
Weight loss  
in SBF (%) 
Maximum dapsone released at pH7 based 
on copolymer composition (x10-2    ) 
IC50 
(g/ml) 
P100 0.2 3 32.5 
P50 1.9 5 42.9 
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could be kept to a minimum by using stoichiometric amounts of the acyl compounds. 
The mono functional derivative of the symmetric sulfamides could be easily isolated 
and both unreacted dapsone and bis-acrylated derivatives were removed using 
recrystallization techniques [18]. Although a modest yield is obtained, this simple and 
easy synthetic process of obtaining DapMa did not warrant further optimisation in 
order to increase the yield since sufficient amounts of the desired monomer could be 
easily obtained [17]. The 1H and 13C NMR peak assignment is presented in Section 
3.1 and were further supported by the two-dimensional HMQC spectra (Figure 4) 
and by previous works reporting NMR studies on (4-substituted aryl) sulfones which 
shown peak assignments in concordance with the reported here [19]. The amidation 
reaction was confirmed by the appearance of the bands corresponding to the 
methacrylic residue (5.8 and 5.5 ppm) and amide proton (10.1 ppm). 
 HEMA monomer is known to impart a certain degree of ductility and 
hydrophilicity to polymeric systems and is beneficial for tuning mechanical and 
biological properties thus makes it a candidate of choice for biocompatible polymer 
drug conjugates preparation. Both P100 and P50 linear polymers were characterised 
by FTIR and 1H and 13C NMR spectroscopies. The lack of unconverted residual 
monomers within the isolated polymers was confirmed by the absence of the 
characteristic 1H-NMR resonance signals assigned to methacrylic protons (5.80 and 
5.54 ppm) and IR –C=CH2 band (1,640 cm
-1) as observed in the corresponding 
monomer 1H-NMR and FTIR spectra (Figure 5 and Figure 6 respectively) indicating 
that the polymerisation reaction proceeded via the methacrylic double bonds to yield 
hydrocarbon macromolecular chains with pendant dapsone and hydroxyethanol 
moieties. Solubility is a very important property of all polymeric biomaterials in 
general and of these dapsone-conjugates in particular as it determines the synthetic 
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methodologies and plays a key role in the bioactivity and degradability of these 
polymers. Linear polymers of dapsone P100 and P50 are fully soluble in organic 
polar solvents and poorly soluble in water. However, when the reaction was carried 
out in the presence of a crosslinking agent, insoluble polymers were obtained, 
indicating the formation of a cross-linked network with dimensional stability 
permitting their use for in vitro drug release and degradation studies while keeping 
the dapsone sequence distribution along the macromolecular microstructure as 
determined for the linear copolymers.  
The DapMA homo and copolymers were soluble in DMF, and the number 
average molecular weight values determined by SEC were relatively high (Mn > 
50kDa) (Table 1) with polydispersity indices near to 2.0 as expected for conventional 
free-radical reaction processes and therefore confirming this polymerization 
mechanism proposed. 
The four degradation stages of p(DapMA-co-HEMA) copolymer suggested a 
degradation mechanism similar to the described for analogue acrylic polymers. 
According to well established theories [20, 21], the first stage of degradation 
originates from sterically hindered linkages that result from head-to-head coupling 
during polymerisation. The second stage of degradation is attributed to the 
decomposition of the vinylidene chain end due to disproportionation, with the rest of 
the stages being attributed to random scission of the main chain leading to 
depolymerisation of the acrylic polymer. In contrast, the p(DapMA) homopolymer 
thermogram suggesting the absence of head-to-head coupling reactions during the 
polymerisation and absence of vinylidene chain ends. The higher stability of 
p(DapMA) can be associated with the stabilization of the free radicals produced in 
the thermal degradation due to the presence of dapsone moiety that provide with 
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antioxidant properties associate to its capacity for stabilize free radicals and radical 
scavenger action [22]. This observation is akin to anti-oxidant properties previously 
described for dapsone and thus beneficial when the polymer interacts with cells 
under physiological conditions [23]. 
EGDMA constitutes a common reagent for preparing biocompatible 
crosslinked polymers due to its effectiveness and desired polymerization kinetics 
[24]. The aim of crosslinking the linear P50 and P100 polymers was to prepare 
insoluble matrices with a desired size and shape to support the in vitro drug release 
and degradation experiments. Release of dapsone was studied using a UV detector, 
which is a simple, fast and practical method with a detection limit of 2 mg · mL-1 [25]. 
The results indicated a sustained release from both homopolymer and co-polymer as 
expected for amide linkages (Figure 8) and were comparable at three different pHs 
(acidic, neutral, basic) for all polymer conjugates with a slight increase in dapsone 
release for the P50 copolymers at pH 10.  This mechanism indicates that the 
hydrolysis of the amide groups occurs only along the hydrophobic dapsone 
sequences and water accessibility is facilitated with the presence of HEMA 
sequences. It is important to highlight that the time points selected in this study were 
chosen from an experimental point of view and were not necessarily biologically 
relevant. However, from a biomedical perspective the hydrolysis mechanism by 
which the drug can be delivered is highly dependent on many other factors relative to 
both physical-chemical properties of the polymer drug conjugate, place of action and 
biological and enzymatic activity of the degradation milieu. Amide linkage constitute 
a widespread approach of  drug conjugation towards the greater control over 
pharmacokinetics and targeted delivery where the main release mechanism is 
accepted to be enzymatically mediated (peptidases, matrix metalloproteinase, 
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collagenase, prostate specific membrane antigen, plasmin and others) [26].   The 
biodegradation rate of vinyl copolymers depends on a number of parameters such as 
hydrophilicity/hydrophobicity balance, composition, monomer sequence distribution, 
molecular weight or micro and macrostructure among other biological characteristic 
of the host tissues which drive the degradation mechanism of the macromolecules 
within body environments. It is well known that the degradative process of relatively 
low to medium molecular weight (<100 KDa) (meth)acrylic based copolymers occurs 
first thought the hydrolysis of lateral residues followed by a random excision of the 
main backbone leading to a reduction of molecular weight that permit further bio-
elimination and excretion of degradative products. The copolymers described in this 
work comprise of well-known biocompatible and bioresorbable hydrocarbon 
backbones analogues similar to established systems systems such as 
poly(hydroxymethyl methacylate) and poly(methacrylic acid) that permit us 
hypothesise an analogue biodegradation mechanism in the body [27]. Meanwhile, 
gravimetric degradation studies of samples in buffered fluid showed a negligible loss 
of weight during the course of the experiment, confirming the stability of these 
materials in aqueous conditions. As a result, the in vitro behaviour of the polymers is 
a consequence of the macromolecular composition and not only due to the release 
of low molecular weight compounds. The conjugation of dapsone to macromolecular 
systems thus provides a synthetic route to incorporate this drug into polymeric 
systems, with the potential to synthesize polymers with inherent anti-inflammatory 
action. 
The nitric oxide inhibition assay constitutes a well-established method to 
determine the macrophage mediated in vitro activity of anti-inflammatory polymer 
drug conjugates. This assay consists in the quantification of NO production in 
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macrophage cultures through activation of inducible nitric oxide synthase by a pro-
inflammatory LPS before the evaluation of NO inhibition activity from extracts of the 
samples [11, 28]. The inhibitory effects of the dapsone polymers on LPS treated cells 
indicate good anti-inflammatory response for all samples with NO inhibition (mean 
ranges P100: 67-83 % and P50 67-90 %) with a maximum NO inhibition capacity 
between the two copolymers significantly higher for P50 after 24 hours of incubation 
(p > 0.05), corresponding to a qualitative anti-inflammatory activity order of P50 > 
P100. This activity sequence indicates that despite HEMA monomer not possessing 
inflammatory effects by itself, its presence in the macromolecule contributes to a 
synergistic effect in improving the overall anti-inflammatory capacity of dapsone 
mainly related to the dapsone release mechanism. In addition, the incorporation of 
HEMA into the co-polymers reduced their cytotoxicity as resulted from their higher 
IC50 values.  
 
5. Conclusions 
The synthesis of dapsone-conjugated methacrylic monomer and polymers provides 
a new approach of obtaining high molecular weight macromolecular systems with in 
vitro anti-inflammatory properties. This approach will enable exploiting the clinical 
applications of dapsone further and has great potential in the development of 
advanced anti-inflammatory therapies. 
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Figure 1. Chemical structures of dapsone and its derivative monomers 
dapsone methacrylamide (DapMA) and bis-methacrylamide (DapBMA). 
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Figure 2. Synthetic route for the preparation of dapsone conjugated monomer 
DapMA, and polymers p(DapMA) and p(DapMA-co-HEMA).  
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Figure 3. Assignment and 1H and 13C NMR spectra of the dapsone-
conjugated monomer DapMA in DMSO-d6 at 25 °C. 
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Figure 4. 1H-13C HMQC spectra of the dapsone-conjugated monomer DapMA in 
DMSO-d6 at 25 °C. 
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Figure 5. 1H NMR spectra of the linear dapsone-conjugated polymers p(DapMA) 
(upper) and p(DapMA-co-HEMA) (lower) in DMSO-d6 at 25 °C. 
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Figure 6. Normalized ATR-FTIR spectra of Dapsone, DapMA monomer and linear 
dapsone-conjugated polymers p(DapMA) (P100) and p(DapMA-co-HEMA) (P50). 
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Figure 7. TGA (upper) and DTG (lower) curves of dapsone-conjugated polymers 
p(DapMA) (P100) and p(DapMA-co-HEMA) (P50) 
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Figure 8. Cumulative released dapsone from conjugated polymers p(DapMA) (P100) 
and p(DapMA-co-HEMA) (P50) at pH 10 (squares), pH 7 (triangles) and pH 3 
(spheres) in the time frame of 21 days. 
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Figure 9. Inhibitory effects of p(DapMA) (P100) and p(DapMA-co-HEMA) (P50) 
polymers on nitric oxide production in LPS-stimulated RAW 264.7 cells (upper) and 
relative cell viability (lower) of the treated cells with the LPS and polymers. The 
results were normalized respect to the corresponding blanks and significant 
differences calculated with respective to LPS control (* p>0.05) and between 
samples (§ p>0.05). 
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Figure 10. Comparison of dose–response curves of dapsone-conjugated polymers 
p(DapMA) (P100) and p(DapMA-co-HEMA) (P50) normalised against control cultures 
with no polymers added. From these diagrams the IC50 values were determined.  
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Statement of Significance  
The dapsone-conjugated methacrylic monomer and polymer derivatives with anti-
inflammatory properties described are previously unreported. The scientific impact of 
this work lies in its potential to expand the clinical applications of dapsone toward the 
development of advanced anti-inflammatory therapies based on polymer-therapeutic 
approaches. These approaches facilitate the treatment of existing rare auto-immune 
and other inflammatory related diseases. 
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